pkc d -ptyr 311
DESCRIPTION
0. 0.5. 1. 2. Thr (min). eNOS. PKC d -pTyr 311. PKC d. †. eNOS-pSer 1179. eNOS-pThr 497. eNOS. A. B. *. 125. *. 100. 75. eNOS-p (%). †. 50. 25. 0. Thr. -. +. -. +. -. +. DMSO. Rott. LY. eNOS-pSer 1179. D. †. 150. 125. C. - PowerPoint PPT PresentationTRANSCRIPT
A
PKC-pTyr311
PKC
0 0.5 1 2 Thr (min)
B
C
D
DMSO
- +
Rott LY
eNOS-pSer1179
eNOS
- + - + Thr
- +
Basal A23
eNOS-pSer1179
eNOS
Rott - +
eNO
S-p
(%
)
- +
- - pre co
Thr
eNOS-pSer1179
eNOS
eNOS-pThr497
PMA
+ +
eNO
S-p
(%
) †
On Line Figure I. A. HUVECs pretreated with 10 mol/L rottlerin (Rott), 10 mol/L LY294002 (LY), or control vehicle (0.1% DMSO) for 30 min were stimulated with 10 U/mL thrombin (Thr) for 1 min. B. BAECs were stimulated with thrombin for the indicated time periods. PKC Tyr311 phosphorylation was evaluated by immunoblotting. C. BAECs pretreated with or without 10 mol/L rottlerin (Rott) for 30 min were stimulated with 10 mol/L A23187 for 1 min. D. BAECs co-treated (co) or pretreated (pre 5 min) with 1 mol/L PMA were stimulated with 10 U/mL thrombin for 1 min. These data shown are representative of 3 separate experiments giving similar results (mean + SEM. *p < 0.05 compared to basal. †p < 0.05 compared to stimulated control.).
†
0
25
50
75
100
pSer1179
pThr497†
0 25
50 75
100 125 150
eNO
S-p
(%
)
†
**
0
25
50
75
100
125